Impact of empagliflozin in patients with diabetes and heart failure

David Pham, Natalia De Albuquerque Rocha, Darren K McGuire, Ian J Neeland

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.

Original languageEnglish (US)
Pages (from-to)144-151
Number of pages8
JournalTrends in Cardiovascular Medicine
Issue number2
StatePublished - Feb 1 2017


  • Empagliflozin
  • Heart failure
  • SGLT2 inhibitor
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Impact of empagliflozin in patients with diabetes and heart failure'. Together they form a unique fingerprint.

Cite this